Olaparib
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety
In vitro assessment of the roles of drug transporters in the disposition and drug–drug interaction potential of olaparib